Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amneal Pharmaceuticals, Inc. - Class A Common Stock (NQ:AMRX)

9.440 +0.050 (+0.53%)
Streaming Delayed Price Updated: 12:34 PM EDT, Aug 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 852,890
Open 9.430
Bid (Size) 9.430 (17)
Ask (Size) 9.440 (13)
Prev. Close 9.390
Today's Range 9.390 - 9.590
52wk Range 6.685 - 9.475
Shares Outstanding 1,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Avantor, Viatris, and Amneal Stocks Trade Up, What You Need To Know
A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer... 
Via StockStory
Topics Artificial Intelligence Economy
AMRX Q2 Deep Dive: New Product Launches and Specialty Momentum Shape Guidance
Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) missed Wall Street’s revenue expectations in Q2 CY2025 as sales rose 3.2% year on year to $724.5 million. On the other hand, the company’s... 
Via StockStory

Performance

YTD
+21.6%
+21.6%
1 Month
+14.1%
+14.1%
3 Month
+25.9%
+25.9%
6 Month
+19.3%
+19.3%
1 Year
+20.9%
+20.9%

More News

Read More
Revvity, Avantor, Azenta, Bio-Techne, and Amneal Shares Skyrocket, What You Need To Know
Via StockStory
Topics Bonds Economy Stocks
Earnings Scheduled For August 5, 2025
Via Benzinga
1 Value Stock to Keep an Eye On and 2 Facing Challenges
Via StockStory
Amneal (AMRX) Q2 EPS Jumps 56%
Via The Motley Fool
Topics Economy
Amneal Pharmaceuticals Inc (NASDAQ:AMRX) Reports Mixed Q2 2025 Results: Earnings Beat, Revenue Miss
Via Chartmill
Topics Earnings
Amneal (NASDAQ:AMRX) Misses Q2 Sales Targets
Via StockStory
A Peek at Amneal Pharmaceuticals's Future Earnings
Via Benzinga
Amneal Reports Second Quarter 2025 Financial Results
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
Amneal Earnings: What To Look For From AMRX
Via StockStory
Topics Artificial Intelligence Government World Trade
Q1 Earnings Highs And Lows: Amneal (NASDAQ:AMRX) Vs The Rest Of The Generic Pharmaceuticals Stocks
Via StockStory
Topics Artificial Intelligence Intellectual Property
Amneal Announces Proposed Refinancing of Existing Credit Agreement, including Private Offering of Senior Secured Notes Due 2032
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
Amneal Reports Certain Preliminary Second Quarter 2025 Financial Results
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
3 Profitable Stocks with Warning Signs
Via StockStory
Amneal to Report Second Quarter 2025 Results on August 5, 2025
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
1 Small-Cap Stock to Consider Right Now and 2 to Keep Off Your Radar
Via StockStory
Topics Supply Chain
Amneal Highlights Positive Topline Results from Confirmatory Clinical Study of Biosimilar Candidate to XOLAIR(R) (omalizumab), Developed by Kashiv BioSciences
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
Goldman Sachs Bullish On Branded Drug Upside At Teva: What About Viatris?
Via Benzinga
3 of Wall Street’s Favorite Stocks in the Doghouse
Via StockStory
Topics Intellectual Property
Amneal Recalls Three Lots Of UTI Drug Over Concerns of Microbial Contamination: Retail Sticks To Bearish Territory
Via Stocktwits
Topics Artificial Intelligence Product Recall
Amneal to Participate at Upcoming Investor Conferences in June
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
AMRX Q1 Earnings Call: Miss on Revenue, Margin Expansion, and Product Pipeline Progress
Via StockStory
Topics Supply Chain
Amneal Gets FDA Nod For Self-Administrable Migraine Injection
Via Stocktwits
Topics Data Breach

Frequently Asked Questions

Is Amneal Pharmaceuticals, Inc. - Class A Common Stock publicly traded?
Yes, Amneal Pharmaceuticals, Inc. - Class A Common Stock is publicly traded.
What exchange does Amneal Pharmaceuticals, Inc. - Class A Common Stock trade on?
Amneal Pharmaceuticals, Inc. - Class A Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Amneal Pharmaceuticals, Inc. - Class A Common Stock?
The ticker symbol for Amneal Pharmaceuticals, Inc. - Class A Common Stock is AMRX on the Nasdaq Stock Market
What is the current price of Amneal Pharmaceuticals, Inc. - Class A Common Stock?
The current price of Amneal Pharmaceuticals, Inc. - Class A Common Stock is 9.440
When was Amneal Pharmaceuticals, Inc. - Class A Common Stock last traded?
The last trade of Amneal Pharmaceuticals, Inc. - Class A Common Stock was at 08/15/25 12:34 PM ET
What is the market capitalization of Amneal Pharmaceuticals, Inc. - Class A Common Stock?
The market capitalization of Amneal Pharmaceuticals, Inc. - Class A Common Stock is 9.44K
How many shares of Amneal Pharmaceuticals, Inc. - Class A Common Stock are outstanding?
Amneal Pharmaceuticals, Inc. - Class A Common Stock has 9K shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.